Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors.
Journal
Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
received:
20
08
2020
accepted:
06
11
2020
pubmed:
13
11
2020
medline:
13
1
2021
entrez:
12
11
2020
Statut:
ppublish
Résumé
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Africa is poorly described. The first case of SARS-CoV-2 in Kenya was reported on 12 March 2020, and an overwhelming number of cases and deaths were expected, but by 31 July 2020, there were only 20,636 cases and 341 deaths. However, the extent of SARS-CoV-2 exposure in the community remains unknown. We determined the prevalence of anti-SARS-CoV-2 immunoglobulin G among blood donors in Kenya in April-June 2020. Crude seroprevalence was 5.6% (174 of 3098). Population-weighted, test-performance-adjusted national seroprevalence was 4.3% (95% confidence interval, 2.9 to 5.8%) and was highest in urban counties Mombasa (8.0%), Nairobi (7.3%), and Kisumu (5.5%). SARS-CoV-2 exposure is more extensive than indicated by case-based surveillance, and these results will help guide the pandemic response in Kenya and across Africa.
Identifiants
pubmed: 33177105
pii: science.abe1916
doi: 10.1126/science.abe1916
pmc: PMC7877494
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-82Subventions
Organisme : Medical Research Council
ID : MR/R006083/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S005293/1
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021, American Association for the Advancement of Science.
Références
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Sci Immunol. 2020 Jul 29;5(49):
pubmed: 32727884
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
JAMA Intern Med. 2020 Jul 21;:
pubmed: 32692365
Proc Natl Acad Sci U S A. 2020 May 5;117(18):9696-9698
pubmed: 32300018
Science. 2021 Jan 1;371(6524):79-82
pubmed: 33177105
J Med Virol. 2020 Oct;92(10):1795-1796
pubmed: 32311142
J R Stat Soc Ser C Appl Stat. 2020 Aug 13;69(5):1269-1283
pubmed: 37252679
BMJ Glob Health. 2020 May;5(5):
pubmed: 32451367
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Nat Med. 2020 Aug;26(8):1193-1195
pubmed: 32504052
Blood Transfus. 2021 May;19(3):181-189
pubmed: 33539289
Wellcome Open Res. 2020 Jun 26;5:150
pubmed: 32995556
Nat Rev Immunol. 2020 Aug;20(8):457-458
pubmed: 32636479
Rev Saude Publica. 2020;54:69
pubmed: 32638883
Science. 2020 Aug 7;369(6504):624-626
pubmed: 32764055
Lancet Glob Health. 2020 Jul;8(7):e901-e908
pubmed: 32405459